In the past week, CHRS stock has gone down by -7.14%, with a monthly decline of -35.58% and a quarterly plunge of -49.62%. The volatility ratio for the week is 7.10%, and the volatility levels for the last 30 days are 6.93% for Coherus Biosciences Inc The simple moving average for the past 20 days is -20.92% for CHRS’s stock, with a -61.83% simple moving average for the past 200 days.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
The 36-month beta value for CHRS is at 0.68. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CHRS is 110.58M, and currently, shorts hold a 27.00% of that float. The average trading volume for CHRS on November 05, 2024 was 2.29M shares.
CHRS) stock’s latest price update
Coherus Biosciences Inc (NASDAQ: CHRS)’s stock price has plunge by -7.33relation to previous closing price of 0.72. Nevertheless, the company has seen a -7.14% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-30 that REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -36.11% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.04% of loss for the given period.
Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares sank -37.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.80% lower at present.
During the last 5 trading sessions, CHRS fell by -7.14%, which changed the moving average for the period of 200-days by -72.54% in comparison to the 20-day moving average, which settled at $0.8475. In addition, Coherus Biosciences Inc saw -79.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRS starting from Lanfear Dennis M, who sale 223,100 shares at the price of $2.02 back on Nov 22 ’23. After this action, Lanfear Dennis M now owns 731,693 shares of Coherus Biosciences Inc, valued at $449,770 using the latest closing price.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.51 for the present operating margin
- 0.4 for the gross margin
The net margin for Coherus Biosciences Inc stands at -0.1. The total capital return value is set at -0.74.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at -3.5. The interest coverage ratio of the stock is -9.32.
Currently, EBITDA for the company is -189.41 million with net debt to EBITDA at -0.91. When we switch over and look at the enterprise to sales, we see a ratio of 0.7. The receivables turnover for the company is 0.98for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
